Prana commences US Investor Roadshow
Prana and Credit Suisse begin non-deal investor roadshow in US
JANUARY 2014: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse.
The Corporate presentation includes:
- Information on the Company’s development programs and upcoming catalysts;
- Overview of the Huntington’s disease phase 2 clinical trial which is nearing the
- reporting of major clinical results; and
- Overview of the Alzheimer’s disease phase 2 clinical trial, which is expected to report
- in March 2014.
Mr Geoffrey Kempler, President and Chief Executive Officer and Professor Rudy Tanzi,
Prana’s Chief Scientific Advisor and Professor of Neurology, Harvard Medical School will be
The full presentation is available in the Investor Information section under ASX Announcements.